Posted on June 17th, 2013 by
The targeted drug Nexavar® (sorafenib) delays the growth of treatment-resistant, differentiated thyroid cancers. These results—from a Phase III clinical trial—were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Differentiated thyroid cancer is the most common type of thyroid cancer and can often be cured with surgery and radioactive iodine (RAI) treatment. In some cases, however, the cancer is resistant to RAI. RAI-resistant thyroid cancers have had few effective treatment options.
Nexavar is taken orally and targets certain proteins that contribute to cancer growth. It is used to treat advanced kidney cancer and inoperable liver cancer.
To evaluate Nexavar in the treatment of thyroid cancer, researchers conducted a Phase III trial (the DECISION trial). The study enrolled 417 patients with metastatic, RAI-resistant, differentiated thyroid cancer. Patients were treated with either Nexavar or a placebo.
These results suggest that Nexavar almost doubles progression-free survival among patients with treatment-resistant, metastatic, differentiated thyroid cancer. If Nexavar is approved for this type of cancer, it would be the first new drug in decades to demonstrate effectiveness for this group of patients.
Reference: Brose MS, Nutting C, Jarzab B et al. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. Presented at the 49th Annual Meeting of the American Society of Clinical Oncology. May 31-June 4, 2013; Chicago, IL. Abstract 4.
Copyright © 2013 CancerConsultants. All Rights Reserved.
Tags: Thyroid Cancer
You must be logged-in to the site to post a comment.